Restanza Superiority Trials Intended To Avoid Non-Inferiority "Quagmire"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Advanced Life Sciences CEO Michael Flavin decided a pair of superiority trials was the best way to prove the efficacy of the company’s Restanza in community-acquired bacterial pneumonia, given the "stalemate" at FDA regarding the use of non-inferiority trials in antibiotics.
You may also be interested in...
FDA Encourages Sponsors Of Hypertension Drugs To Promote Their Cardiovascular Benefits
Final guidance allowing class-wide outcomes claims includes suggested language for both advertising and labeling.
NICE-Style Value-Based Pricing Might Actually Boost Antibiotic Sales In U.S.
Antibiotic development could expand if the U.S. adopted a system to evaluate the drugs’ effectiveness and value to society for reimbursement purposes, similar to that of the British National Institute for Health and Clinical Excellence, according to an article in the Sept. 7 issue of the journal Health Affairs.
NICE-Style Value-Based Pricing Might Actually Boost Antibiotic Sales In U.S.
Antibiotic development could expand if the U.S. adopted a system to evaluate the drugs’ effectiveness and value to society for reimbursement purposes, similar to that of the British National Institute for Health and Clinical Excellence, according to an article in the Sept. 7 issue of the journal Health Affairs.